Cartesian Therapeutics(RNAC)

Focus: Cartesian Therapeutics is a public biotech company developing mRNA-engineered cell therapies, operating at a very small scale with 1-50 employees focused on autologous cell therapy programs.

Gene Therapy Cell Therapy

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1-50

Open Jobs

About Cartesian Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Cartesian Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$39M

Pipeline & Clinical Trials

Descartes-25

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT05113342Descartes-25 in Relapsed/Refractory Multiple Myeloma

Phase 1

Help build intelligence for Cartesian Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform company with novel mRNA-engineered cell therapy technology addressing multiple serious indications across autoimmune, oncology, and inflammatory disease
Public company status provides equity upside potential and stability compared to private biotech, with $213M cash runway as of FY 2025
Diversified pipeline with 12 active trials spanning Phase 1-3, including late-stage Phase 3 program in myasthenia gravis offering near-term catalysts

Watch Out For

Extremely small headcount (1-50 employees) limits career infrastructure, mentorship, and internal mobility opportunities typical of larger organizations
Burning $77M annually with only $39M revenue (FY 2025), creating existential pressure despite adequate current cash reserves; R&D intensity of 116% unsustainable long-term
No current active job postings and minimal hiring activity signal organizational constraints; company is pre-commercial with unproven commercial execution

Generated by Claude from Cartesian Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Descartes 30

Acute Respiratory Distress Syndrome

PHASE_1

Clinical Trials (1)

NCT04524962Study of Descartes-30 in Acute Respiratory Distress Syndrome

Phase 1

Descartes-11

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT03994705Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Descartes-15

Refractory Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT06304636Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Descartes-08

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT03448978Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1

Descartes-08

Childhood-onset Systemic Lupus Erythematous

PHASE_1_2

Clinical Trials (1)

NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Phase 1/2

Descartes 11

Multiple Myeloma

PHASE_2

Clinical Trials (1)

NCT04436029Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Descartes-08

Systemic Lupus Erythematosus (SLE)

PHASE_2

Clinical Trials (1)

NCT06038474Descartes-08 for Patients With Systemic Lupus Erythematosus

Phase 2

Descartes-08

Myasthenia Gravis, Generalized

PHASE_2

Clinical Trials (1)

NCT04146051Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Phase 2

Descartes 08

Myeloma Multiple

PHASE_2

Clinical Trials (1)

NCT04816526Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2

Descartes-08

Antisynthetase Syndrome

PHASE_2

Clinical Trials (1)

NCT07391605Descartes-08 in Autoantibody Myositis

Phase 2

Decartes-08

Myasthaenia Gravis

PHASE_3

Clinical Trials (1)

NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis